People · Operator
Named in public records as an officer, director or promoter · active 2017–2017 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Istari Oncology, Inc. | — | Biotechnology | Series C | $48.6M | $1.4B | 2017 |
Henry P. Friedman at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Henry P. Friedman on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Matthew R. Stober | 1 | 2 |
| Robert R. Bonczek | 1 | 2 |
| Sean P. Nolan | 1 | 2 |
| Matthew W. Farber | 1 | 1 |
| William G. Nichols | 1 | 1 |
| Victor R. Sandor | 1 | 1 |
| Dani P. Bolognesi | 1 | 1 |
| Robert J. Bonczek | 1 | 1 |
| Timothy J. Creech | 1 | 1 |
| Darell D. Bigner | 1 | 1 |
| Raymond R. Cheong | 1 | 1 |
| Marc G. Banjak | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.